Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Diagnostics Office Seeks Bigger Role In Personalized Medicine

This article was originally published in The Pink Sheet Daily

Executive Summary

Historically overlooked office gets leadership, money and hiring okay needed to ramp up its contribution to pan-FDA initiatives, policy discussions.

You may also be interested in...



People In Brief

Peer Portner: The pioneer of the first electrical left ventricular assist device died Feb. 9, from cancer. Peer Portner, a Ph.D. trained in nuclear physics, lead a multidisciplinary team at Stanford University in the 1970s to develop the Novacor LVAD, used in the first bridge-to-transplant procedure in 1984. Portner also founded Novacor Medical, which was acquired by Baxter Healthcare in 1988. WorldHeart acquired the Novacor technology in 2000 and continues to market, on a limited basis, an updated version of the product as a bridge-to-transplant pump, and, in Europe, as a longer-term destination therapy

Personalized Partnering: Drug, Dx Firms Should Team, Not Necessarily Merge

Industry leaders disagree on whether collaborations or mergers are the best structure for effective drug/diagnostic collaborations

Cross-Center CDRH Matrix Goes Live After Six Months Of Ground Work

Recently appointed leaders of CDRH's new cross-center post-market safety "matrix" organization are officially on the job, beginning July 14, after six months of initial training and testing of the collaborative system

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069340

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel